AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

XTPL S.A.

Legal Proceedings Report Mar 27, 2025

5868_rns_2025-03-27_deab5f30-455b-4458-932d-6e3f2aad7f2e.html

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

Report Content Title:

Patent approval by the United States Patent and Trademark Office (USPTO).

Legal basis:

Article 17 (1) MAR - confidential information

Content of the Report:

The Management Board of XTPL ("Issuer", "Company", "XTPL") herebyreports that on 25 March 2025 it received the notice of allowance andinformation related to allowed claims issued by the United States Patentand Trademark Office (USPTO). The patent application has been examinedand is allowed for issuance as a patent for an invention "Metallicnanoparticle composition dispenser and method of dispensing metallicnanoparticle composition".

The application procedure for this patent was initiated on 7 May 2021.The final formal requirement for obtaining the patent is to pay thenecessary fee. Should the requirement not be met, the Company willcommunicate this in a separate current report.

The patent protection will increase the value of the potentialcommercialization of the Company's technology with respect to theIssuer's technological solutions for the next generation electronicsmarket. The reported event confirms continued delivery of the Company'sstrategy of building a patent cloud for its proprietary technology andproducts, which will contribute to building the Issuer's credibilityamong potential industrial clients.

In view of the above, and considering the confirmation of uniqueness ofthe Company's technological solutions, and then the outlook for theIssuer's perception by investors, the Issuer's Management Board hasdecided that the notice of allowance and information related to allowedclaims should be deemed confidential information. For this reason, inthe opinion of the Management Board, the information meets the criteriaset out in Article 7(1) of the MAR.

At the same time, the Management Board informs that due to a significantincrease in the number of patents granted, the Company will ceasepublishing current reports on each individual patent approval, andinformation on this matter will be collectively presented in theCompany's periodic reports.

Talk to a Data Expert

Have a question? We'll get back to you promptly.